Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

November 06, 2024

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

News Conference News VIVA 2022

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

November 04, 2022

Vascular Care Falls Short Before Amputation for CLI: Medicare Analysis

News Conference News VIVA 2021

Vascular Care Falls Short Before Amputation for CLI: Medicare Analysis

October 06, 2021

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

News Conference News VIVA 2020

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

November 11, 2020

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

News Conference News VIVA 2020

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

November 09, 2020

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

News Conference News VIVA 2019

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

November 08, 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

News Conference News VIVA 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

November 06, 2019

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

November 15, 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

November 13, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.